Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Brian Godman, Andrew Hill, Steven Simoens, Amanj Kurdi, Jolanta Gulbinovič , Antony Martin, Angela Timoney, Dzintars Gotham, Janet Wale, Tomasz Bochenek , Celia Rothe, Iris Hoxha, Admir Malaj, Christian Hierländer, Robert Sauermann, Wouter Hamelinck, Zornitza Mitkova, Guenka Petrova, Ott Laius, Catherine Sermet & 28 others Irene Langer, Gisbert Selke, John Yfantopoulos, Roberta Joppi, Arianit Jakupi, Elita Poplavska, Ieva Greiciute-Kuprijanov, Patricia Vella Bonanno, JF Piepenbrink, Vincent de Valk, Carolin Hagen, Anne Marthe Ringerud, Robert Plisko, Magdalene Wladysiuk, Vanda Marković-Peković, Nataša Grubiša, Ileana Mardare, Tanja Novakovic, Tatjana Ponorac, Mark Parker, Jurij Fürst, Dominic Tomek, Mercè Obach Cortadellas, Corrine Zara, Maria Juhasz-Haverinen, Peter Skiold, Stuart McTaggart, Alan Haycox

Research output: Contribution to journalArticle

Abstract

Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer
LanguageEnglish
JournalGenerics and Biosimilars Initiative journal
Publication statusAccepted/In press - 22 Mar 2019

Fingerprint

Mouth Neoplasms
Medicine
Costs and Cost Analysis
Costs
Health
temozolomide
Oncology
Neoplasms
Population Density
Drug Substitution
Oral Medicine
Qualitative Research
Financial Management
Health Expenditures
Health Personnel
Sustainable development
Economics
Databases
Substitution reactions
Personnel

Keywords

  • cancer
  • pricing
  • generics
  • generic regulations
  • Europe
  • health policy

Cite this

Godman, Brian ; Hill, Andrew ; Simoens, Steven ; Kurdi, Amanj ; Gulbinovič , Jolanta ; Martin, Antony ; Timoney, Angela ; Gotham, Dzintars ; Wale, Janet ; Bochenek , Tomasz ; Rothe, Celia ; Hoxha, Iris ; Malaj, Admir ; Hierländer, Christian ; Sauermann, Robert ; Hamelinck, Wouter ; Mitkova, Zornitza ; Petrova, Guenka ; Laius, Ott ; Sermet, Catherine ; Langer, Irene ; Selke, Gisbert ; Yfantopoulos, John ; Joppi, Roberta ; Jakupi, Arianit ; Poplavska, Elita ; Greiciute-Kuprijanov, Ieva ; Vella Bonanno, Patricia ; Piepenbrink, JF ; de Valk, Vincent ; Hagen, Carolin ; Ringerud, Anne Marthe ; Plisko, Robert ; Wladysiuk, Magdalene ; Marković-Peković, Vanda ; Grubiša, Nataša ; Mardare, Ileana ; Novakovic, Tanja ; Ponorac, Tatjana ; Parker, Mark ; Fürst, Jurij ; Tomek, Dominic ; Cortadellas, Mercè Obach ; Zara, Corrine ; Juhasz-Haverinen, Maria ; Skiold, Peter ; McTaggart, Stuart ; Haycox, Alan. / Pricing of oral generic cancer medicines in 25 European countries; findings and implications. In: Generics and Biosimilars Initiative journal. 2019.
@article{0ccc6928568c4ea8b9887f78c3eb19dd,
title = "Pricing of oral generic cancer medicines in 25 European countries; findings and implications",
abstract = "Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1{\%}), generic imatinib (up to -97.8{\%}) and generic temozolomide (up to -80.7{\%}). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer",
keywords = "cancer, pricing, generics, generic regulations, Europe, health policy",
author = "Brian Godman and Andrew Hill and Steven Simoens and Amanj Kurdi and Jolanta Gulbinovič and Antony Martin and Angela Timoney and Dzintars Gotham and Janet Wale and Tomasz Bochenek and Celia Rothe and Iris Hoxha and Admir Malaj and Christian Hierl{\"a}nder and Robert Sauermann and Wouter Hamelinck and Zornitza Mitkova and Guenka Petrova and Ott Laius and Catherine Sermet and Irene Langer and Gisbert Selke and John Yfantopoulos and Roberta Joppi and Arianit Jakupi and Elita Poplavska and Ieva Greiciute-Kuprijanov and {Vella Bonanno}, Patricia and JF Piepenbrink and {de Valk}, Vincent and Carolin Hagen and Ringerud, {Anne Marthe} and Robert Plisko and Magdalene Wladysiuk and Vanda Marković-Peković and Nataša Grubiša and Ileana Mardare and Tanja Novakovic and Tatjana Ponorac and Mark Parker and Jurij F{\"u}rst and Dominic Tomek and Cortadellas, {Merc{\`e} Obach} and Corrine Zara and Maria Juhasz-Haverinen and Peter Skiold and Stuart McTaggart and Alan Haycox",
year = "2019",
month = "3",
day = "22",
language = "English",
journal = "Generics and Biosimilars Initiative journal",
issn = "2033-6403",

}

Godman, B, Hill, A, Simoens, S, Kurdi, A, Gulbinovič , J, Martin, A, Timoney, A, Gotham, D, Wale, J, Bochenek , T, Rothe, C, Hoxha, I, Malaj, A, Hierländer, C, Sauermann, R, Hamelinck, W, Mitkova, Z, Petrova, G, Laius, O, Sermet, C, Langer, I, Selke, G, Yfantopoulos, J, Joppi, R, Jakupi, A, Poplavska, E, Greiciute-Kuprijanov, I, Vella Bonanno, P, Piepenbrink, JF, de Valk, V, Hagen, C, Ringerud, AM, Plisko, R, Wladysiuk, M, Marković-Peković, V, Grubiša, N, Mardare, I, Novakovic, T, Ponorac, T, Parker, M, Fürst, J, Tomek, D, Cortadellas, MO, Zara, C, Juhasz-Haverinen, M, Skiold, P, McTaggart, S & Haycox, A 2019, 'Pricing of oral generic cancer medicines in 25 European countries; findings and implications' Generics and Biosimilars Initiative journal.

Pricing of oral generic cancer medicines in 25 European countries; findings and implications. / Godman, Brian; Hill, Andrew; Simoens, Steven; Kurdi, Amanj; Gulbinovič , Jolanta; Martin, Antony; Timoney, Angela; Gotham, Dzintars ; Wale, Janet; Bochenek , Tomasz; Rothe, Celia; Hoxha, Iris; Malaj, Admir; Hierländer, Christian ; Sauermann, Robert; Hamelinck, Wouter; Mitkova, Zornitza; Petrova, Guenka; Laius, Ott; Sermet, Catherine; Langer, Irene; Selke, Gisbert; Yfantopoulos, John; Joppi, Roberta; Jakupi, Arianit; Poplavska, Elita; Greiciute-Kuprijanov, Ieva; Vella Bonanno, Patricia; Piepenbrink, JF; de Valk, Vincent; Hagen, Carolin; Ringerud, Anne Marthe; Plisko, Robert; Wladysiuk, Magdalene ; Marković-Peković, Vanda; Grubiša, Nataša; Mardare, Ileana; Novakovic, Tanja; Ponorac, Tatjana; Parker, Mark; Fürst, Jurij; Tomek, Dominic; Cortadellas, Mercè Obach ; Zara, Corrine; Juhasz-Haverinen, Maria; Skiold, Peter; McTaggart, Stuart; Haycox, Alan.

In: Generics and Biosimilars Initiative journal, 22.03.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pricing of oral generic cancer medicines in 25 European countries; findings and implications

AU - Godman, Brian

AU - Hill, Andrew

AU - Simoens, Steven

AU - Kurdi, Amanj

AU - Gulbinovič , Jolanta

AU - Martin, Antony

AU - Timoney, Angela

AU - Gotham, Dzintars

AU - Wale, Janet

AU - Bochenek , Tomasz

AU - Rothe, Celia

AU - Hoxha, Iris

AU - Malaj, Admir

AU - Hierländer, Christian

AU - Sauermann, Robert

AU - Hamelinck, Wouter

AU - Mitkova, Zornitza

AU - Petrova, Guenka

AU - Laius, Ott

AU - Sermet, Catherine

AU - Langer, Irene

AU - Selke, Gisbert

AU - Yfantopoulos, John

AU - Joppi, Roberta

AU - Jakupi, Arianit

AU - Poplavska, Elita

AU - Greiciute-Kuprijanov, Ieva

AU - Vella Bonanno, Patricia

AU - Piepenbrink, JF

AU - de Valk, Vincent

AU - Hagen, Carolin

AU - Ringerud, Anne Marthe

AU - Plisko, Robert

AU - Wladysiuk, Magdalene

AU - Marković-Peković, Vanda

AU - Grubiša, Nataša

AU - Mardare, Ileana

AU - Novakovic, Tanja

AU - Ponorac, Tatjana

AU - Parker, Mark

AU - Fürst, Jurij

AU - Tomek, Dominic

AU - Cortadellas, Mercè Obach

AU - Zara, Corrine

AU - Juhasz-Haverinen, Maria

AU - Skiold, Peter

AU - McTaggart, Stuart

AU - Haycox, Alan

PY - 2019/3/22

Y1 - 2019/3/22

N2 - Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer

AB - Introduction: There are appreciable concerns among European health authorities with growing expenditure on cancer medicines and issues of sustainability. The enhanced use of low cost generics could help. Aims: Consequently, there is a need to comprehensively document current and future arrangements regarding the pricing of generic cancer medicines across Europe, and whether these are indication specific, as well as how this translates into actual prices to provide future direction. Methodology: Mixed method approach with qualitative research among senior health authority personnel and their advisers. Quantitative research via health authority databases to ascertain current prices for oral cancer medicines that had lost their patent and the influence of population size and economics on prices. Results: 25 European countries participated. Currently we see (a) variable approaches to the pricing of generic cancer medicines, which will continue; (b) no concerns with substitution for oral generic cancer medicines; (c) substantial price reductions versus originators for generic capecitabine (up to -93.1%), generic imatinib (up to -97.8%) and generic temozolomide (up to -80.7%). Prices for oncology medicines are not indication specific, and are not affected by population size although influenced by pricing approaches. There have also been price increases for some non-patented cancer medicines following manufacturer changes although now stabilising. Conclusion: The considerable price reductions seen for some generics means health authorities should further encourage the use of generic oncology medicines when they become available to fund increased volumes and new valued cancer medicines. Countries are also starting to address price increases for generics following changes in the manufacturer

KW - cancer

KW - pricing

KW - generics

KW - generic regulations

KW - Europe

KW - health policy

UR - http://gabi-journal.net/

M3 - Article

JO - Generics and Biosimilars Initiative journal

T2 - Generics and Biosimilars Initiative journal

JF - Generics and Biosimilars Initiative journal

SN - 2033-6403

ER -